The Seattle Times · May 6, 2015
Alexion Pharma to pay $8.4B for Synageva BioPharma
FILE – In this Nov. 3, 2011 file photo, Sanj Patel, President and CEO of Synageva BioPharma Corp., attends the opening bell ceremony at Nasdaq in New York. Alexion...Alexion Pharmaceuticals will buy Synageva BioPharma in an $8.4 billion deal for a rare disease-treatment maker that lost nearly $60 million in the first quarter and has no products on the market.
Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4 billion deal for a rare disease treatment maker that lost nearly $60 million in the first quarter and has no products on the market.
